ChromaDex (NASDAQ:CDXC) initiated with Outperform rating and $8 (119% upside) price target at Sturdivant.
Satsuma Pharmaceuticals (NASDAQ:STSA) initiated with Outperform rating at both Evercore ISI and SVB Leerink.
SpringWorks Therapeutics (NASDAQ:SWTX)
initiated with Buy rating and $37 (89% upside) price target at Goldman
Sachs. Initiated with Outperform rating at Cowen and Company. Initiated
with Outperform rating and $33 price target at Wedbush. Initiated with
Outperform rating at JPMorgan.
QIAGEN (NYSE:QGEN) downgraded to Underweight with a $25 (22% downside risk) price target at JPMorgan after the company announced lower-than-expected preliminary sales growth for Q3 after the close yesterday. Shares down 19% premarket.
Nektar Therapeutics (NASDAQ:NKTR) downgraded to Sell with a $16 (14% downside risk) price target at Goldman. Shares down 6% premarket.
Puma Biotechnology (NASDAQ:PBYI) downgraded to Sell with an $8 (21% downside risk) price target at Goldman. Shares down 4% premarket.
https://seekingalpha.com/news/3504397-jpmorgan-downgrades-qiagen-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.